# Inovio Pharmaceuticals (INO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/INO
## Company Profile
- Ticker: INO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Tumor DNA Vaccines, Oncology, Infectious Disease
## Stock Data
- Close: 1.13 USD
- Market cap: 99550616.77 USD
- Last updated: 2026-10-06
## Business Overview
### DNA-Medicine Biotechnology Company
INOVIO develops DNA medicines intended to generate targeted immune responses against HPV-related diseases, cancer, and infectious diseases. Its approach combines optimized plasmid DNA constructs with proprietary electroporation-based delivery devices.
### CELLECTRA Delivery Technology
CELLECTRA devices deliver brief electrical pulses at the administration site to help cells take up plasmid DNA. The platform is designed to generate antigen-specific T-cell and antibody responses while avoiding viral vectors and allowing repeat dosing.
### INO-3107 for Recurrent Respiratory Papillomatosis
INO-3107 is the company's lead DNA medicine and is under FDA review for recurrent respiratory papillomatosis, an HPV-driven disease characterized by recurring airway tumors and repeated surgeries. The treatment is designed to stimulate immune responses against HPV-6 and HPV-11 antigens.
### VGX-3100 Partnered Program
VGX-3100 is being developed by partner ApolloBio in China for cervical high-grade squamous intraepithelial lesions associated with HPV-16 and HPV-18. The program extends INOVIO's DNA-medicine platform into precancerous cervical disease.
### Next-Generation DMAb and DPROT Platforms
INOVIO is also researching DNA-encoded monoclonal antibodies and DNA-encoded proteins. These programs use administered DNA as instructions for the body to produce therapeutic proteins, potentially broadening the platform beyond conventional vaccine-like immune activation.
## Why The Stock Is Moving

As of Oct 6, 2026, INO closed down 1.74% at $1.13. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA PDUFA decision for INO-3107 in recurrent respiratory papillomatosis on October 30, 2026.

## Recent News
- 2023-06-23 20:10 EST — [INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions](https://biopharmsignal.com/news/INO/inovio-announces-notice-of-pendency-and-proposed-settlement-of-stockholder-deriv-04e91627) — Source: Inovio Pharmaceuticals
- 2018-12-04 13:00 EST — [Inovio Announces Initiation of “MD Anderson’s HPV-Related Cancers Moon Shot” Phase 2 Trial in New HPV Indications](https://biopharmsignal.com/news/INO/inovio-announces-initiation-of-md-anderson-s-hpv-related-cancers-moon-shot-phase-81452129) — Source: Inovio Pharmaceuticals
- 2018-11-27 02:35 EST — [Inovio, DNA 암호화 단일클론 항체(dMAb™) 플랫폼의 효능 입증하는 임상전 논문 3건과 2019년 첫 임상시험 계획 발표](https://biopharmsignal.com/news/INO/inovio-dna-dmab-3-2019-575d456e) — Source: Inovio Pharmaceuticals
- 2018-11-27 02:35 EST — [イノビオ社、3件の前臨床試験で同社のDNAコード化モノクローナル抗体 (dMAb™) プラットフォームの効力をさらに実証し、2019年初旬の初回臨床試験に向けて準備を進める](https://biopharmsignal.com/news/INO/3-dna-dmab-2019-c3002d7b) — Source: Inovio Pharmaceuticals
- 2018-11-27 02:35 EST — [Inovio在三項臨床前試驗結果文獻中進一步顯示Inovio的DNA編碼單克隆抗體（dMAb™）平台的療效，並準備在2019年初進行首次臨床試驗](https://biopharmsignal.com/news/INO/inovio-inovio-dna-dmab-2019-9b7c1150) — Source: Inovio Pharmaceuticals